PARP1 and prostate carcinoma: Two case reports described patients with prostate NEC, a highly aggressive histologic subtype of prostate cancer, one with germline and the second with somatic BRCA mutation, confirming platinum and Poly[ADP-ribose] polymerase 1 (PARP) inhibitor sensibility similar to that of malignancies that frequently present this type of alteration (40, 41).